Musculoskeletal DiseasesNutririskNCT05546541
Epidemiology and Nutrition
An observational study of Musculoskeletal Diseases and Osteoarthritis, Knee, run by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio at 1 site in Italy.
Trial summary
The general purpose of this study is to evaluate the relation between the nutritional status of patients, the features of the orthobiologics products used for patients' treatment and the clinical outcomes after one-step conservative regenerative treatment for knee osteoarthritis. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Musculoskeletal Diseases, Osteoarthritis, Knee, Nutrition, Healthy
- How many people
- 88 participants
- Where
- 1 siteItaly
- Study dates
- 29 Sep 2021to 30 Jun 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients affected by knee osteoarthritis undergoing conservative regenerative medicine procedures with autologous material at IRCCS Istituto Ortopedico Galeazzi and participating to the observational study "REGAIN" will be enrolled for this study: 88 patients will be needed: 1. 22 subjects with body mass index (BMI) considered normal weight (≥18.5 and ≤25) undergo to Platelet-Rich Plasma (PRP) treatment; 2. 22 subjects with BMI>25 undergo to PRP treatment; 3. 22 subjects with BMI ≥18.5 and ≤25 undergo to microfragmented adipose tissue treatment; 4. 22 subjects with BMI >25 undergo to microfragmented adipose tissue treatment.
Who may be able to join
- males and females ≥18 and ≤ 65 years;
- presence of knee osteoarthritis;
- indication to regenerative medicine treatments PRP or microfragmented adipose treatment;
- participation to the observational study "REGAIN";
- patients with BMI ≥18.5;
- signature of Informed Consent for the study.
Who cannot join
- patients with BMI <18.5;
- patients who are not able to comply with the study schedule.
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
IRCCS Galeazzi orthopaedic institute
Milan, Italia
Elena Cittera, 0039 02 66214057, mailto:elena.cittera@grupposandonato.it
Paola De Luca, post doc researcher
About this study
Official title: Nutrition as a Risk Factor and Predictor of the Outcome of Orthobiological Treatments for Knee Osteoarthritis
The general purpose of this study is to evaluate the relation between the nutritional status of patients, the features of the orthobiologics products used for patients' treatment and the clinical outcomes after one-step conservative regenerative treatment for knee osteoarthritis.
Read the detailed description
The general purpose of this monocentric, observational with additional procedure (extra routine blood sampling, questionnaires and measurement of Nutritional status), prospective and non-controlled study is to evaluate the relation between the nutritional status of patients, the features of the orthobiologics products used for patients' treatment and the clinical outcomes after one-step conservative regenerative treatment (Platelete rich plasma and micro-fragmented adipose tissue injections) for knee osteoarthritis.The primary outcome of the study will be the identification of the proportion of responders and non-responders patients to the orthobiologic treatment (according to OMERACT-OARSI criteria) at 6-month follow-up. Another primary outcome will be the nutritional status identification of the same patients.
For these purposes the responder or non-responder patients will be identified based on the results of the Visual Analogue Scale (VAS) [the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100; a higher score indicates greater pain intensity no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm)], Tegner-Lysholm Activity Scale and Knee Injury (Scores range from 0=worse disability to 100=less disability) and Osteoarthritis Outcome score (KOOS) (the score is a percentage score from 0 to 100, 0 representing extreme problems and 100 representing no problems) according to the parameters established by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) and Osteoarthritis Research Society International (OARSI) [they cannot be represented by a range of values]. The secondary outcomes of the study will be:
- the identification of the proportion of responders and non-responders patients to the orthobiologic treatment (according to OMERACT-OARSI criteria) at 2 and 12-month follow-up and of their related nutritional status;
- the characterization of the orthobiologic products used for the patient's treatment.
After the ethics committee approval, patients meeting the inclusion criteria undergoing conservative knee regenerative medicine treatments with orthobiologics and participating to the observational study "REGAIN" will be enrolled into the study. The PROMs will be completed by patients based on their clinical condition and on the specific treatment they will receive at the REGAIN Center. The aforementioned PROMs include but are not limited to:
- VAS, Tegner-Lysholm Activity Scale, KOOS. Patients will be asked to filled the PROMs at the time of the enrollment (before the treatment) and then at 2, 6 and 12 months after the treatment.
Blood and nutritional information will be collected only the day of the treatment to allow for evaluation of the possible association between patients' characteristics and treatment outcomes. Blood sampling will be performed to carry out the following laboratory analysis, in detail: complete blood count (cell number/dl), blood glucose (mg/dl), hemoglobin A1C (HbA1c) (mmol/mol), creatinine (mg/dl), Glutamic Oxaloacetic Transaminase (GOT) and Glutamic-Pyruvic Transaminase (GPT) (U/L), C reactive protein (mg/dl), triglycerides (mg/dl), total cholesterol(mg/dl), HDL(mg/dl).
In particular, for patients undergoing a Platelet Rich Plasma (PRP) treatment, a blood sample is already routinely harvested and therefore only an extra test tube will be added to test blood glucose (mg/dl), hemoglobin A1C (HbA1c) (mmol/mol), creatinine (mg/dl), GOT and GPT transaminases (U/L), C reactive protein (mg/dl), triglycerides (mg/dl), total cholesterol(mg/dl), HDL(mg/dl). For patients undergoing a treatment with microfragmented adipose tissue, an ad hoc blood collection will be carried out by filling two test tubes.
Nutritional information include anthropometric measurements, diet history and food consumption questionnaire (24h recall, "How much do i really eat?", Italian Mediterranea Index, anamnesi). Anthropometric measurements include weight (kg) and height (m), waist circumference (cm), arm circumference measurements (cm), biceps, triceps, subscapular and suprailiac folds measurement (mm) (plicometry) through the use of the skinfolder. It should be noted that the skinfolder is only one of the tools used to evaluate the patient's nutritional status, without diagnostic purposes and without the will to investigate anything about the device.
Concerning the orthobiologics characterization, PRP and microfragmented adipose tissue will undergo to different evaluations as per the observational study protocol "REGAIN".
In addition, for the purpose of this study, isolation and characterization of extracellular vesicles derived from PRP and micro fragmented adipose tissue will be performed, in order to deepen the orthobiologic characterization. The following techniques will be applied, where appropriate:
- Count and identification of cells from PRP and microfragmented adipose tissue (hemacytometer, nucleocounter, flow cytometry);
- Extracellular vesicle isolation, count and dimensional analysis (ultracentrifuge, Nanosights);
- Extracellular vesicle marker identification (flow cytometry).
These data will be analyzed for their possible association with nutritional status of the patient and clinical outcomes.
Regardless the specific protocol or investigation, the analysis will not include genomic DNA or diagnostic analysis. All samples (blood and tissues) will be analyzed at Istituto Ortopedico Galeazzi and destroyed at the end of the study. Total duration of this study is of 36 months after approval of Ethical Committee.
- Medical subject headings
- Musculoskeletal Diseases, Osteoarthritis, Knee
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| subjects normal weight undergo to PRP treatment | subjects with body mass index (BMI) considered normal weight (≥18.5 and ≤25) undergo to Platelet-Rich Plasma (PRP) treatment. | |
| subjects overweight undergo to PRP treatment | subjects with BMI values that exceed the normal weight range (BMI>25) undergo to PRP treatment. | |
| subjects with normal weight undergo to microfragmented adipose tissue treatment | subjects with BMI within the considered normal weight range (≥18.5 e ≤25) and undergo to microfragmented adipose tissue treatment. | |
| subjects overweight undergo to microfragmented adipose tissue treatment | subjects with BMI values that exceed the normal weight range undergo to microfragmented adipose tissue treatment. (BMI>25). |
What is being measured
The primary outcome is the main question the study is designed to answer.
6 months follow-up, responders and not responders
Identification of the proportion of responders and non-responders patients to the orthobiologic treatment (according to OMERACT-OARSI criteria) at 6-month follow-up.
Measured: 6 months after treatment
Identification of the nutritional status of patients: Complete blood count
Complete blood count (cell number/dl)
Measured: 10 minutes before the treatment
Identification of the nutritional status of patients: Blood glucose
Blood glucose (mg/dl) measurement
Measured: 10 minutes before the treatment
Identification of the nutritional status of patients: blood Hemoglobin A1C (HbA1c)
Hemoglobin A1C (HbA1c) (mmol/mol) measurement
Measured: 10 minutes before the treatment
Identification of the nutritional status of patients: blood creatinine
Creatinine (mg/dl) measurement
Measured: 10 minutes before the treatment
Identification of the nutritional status of patients: blood Glutamic-Oxaloacetic Transaminase GOT (U/L)
Glutamic-Oxaloacetic Transaminase GOT (U/L) measurement
Measured: 10 minutes before the treatment
Identification of the nutritional status of patients: blood Glutamate Pyruvate Transaminase GPT
Glutamate Pyruvate Transaminase GPT (U/L) measurement
Measured: 10 minutes before the treatment
Identification of the nutritional status of patients: blood C reactive protein
C reactive protein (mg/dl) measurement
Measured: 10 minutes before the treatment
Identification of the nutritional status of patients: blood Triglycerides
Triglycerides (mg/dl) measurement
Measured: 10 minutes before the treatment
Identification of the nutritional status of patients: blood total cholesterol
Total cholesterol (mg/dl) measurement
Measured: 10 minutes before the treatment
Identification of the nutritional status of patients: blood High Density Lipoprotein HDL
High Density Lipoprotein HDL (mg/dl) measurement
Measured: 10 minutes before the treatment
Anthropometric measurement: weight
weight (kg) measurement
Measured: 10 minutes before the treatment
Anthropometric measurement: height
height (m) measurement
Measured: 10 minutes before the treatment
Anthropometric measurement: waist circumference
waist circumference (cm) measurement
Measured: 10 minutes before the treatment
Anthropometric measurement: arm circumference measurements
arm circumference measurements (cm)
Measured: 10 minutes before the treatment
Anthropometric measurement: biceps folds measurement
biceps folds measurement (mm)
Measured: 10 minutes before the treatment
Anthropometric measurement: triceps folds measurement
triceps folds measurement (mm)
Measured: 10 minutes before the treatment
Anthropometric measurement: subscapular folds measurement
subscapular folds measurement (mm)
Measured: 10 minutes before the treatment
Anthropometric measurement: suprailiac folds measurement
suprailiac folds measurement (mm)
Measured: 10 minutes before the treatment
Secondary outcomes (3)
2 months follow-up, responders and not responders
The identification of the proportion of responders and non-responders patients to the orthobiologic treatment (according to OMERACT-OARSI criteria) at 2 months follow-up
Measured: 2 months after treatment
12 months follow-up, responders and not responders
The identification of the proportion of responders and non-responders patients to the orthobiologic treatment (according to OMERACT-OARSI criteria) at 12 months follow-up
Measured: 12 months after treatment
The characterization of the orthobiologic products.
The characterization of the orthobiologic products used for the patient's treatment that include isolation and characterization of extracellular vesicles derived from PRP and micro fragmented adipose tissue.
Measured: 15 minutes after the treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2022
- Study start29 Sep 2021
- Primary completion30 Jun 2023 (estimated)
- Study completion30 Jun 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Musculoskeletal DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 88 participants (estimated)
Sponsor and investigators
- Lead sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05546541
- Sponsor's protocol ID
- Nutririsk
- Acronym
- Nutririsk
- Status last verified
- Sep 2022
- First submitted
- 28 Dec 2021
- Last updated
- 21 Sep 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Nutrition as a Risk Factor and Predictor of the Outcome of Orthobiological Treatments for Knee Osteoarthritis
- ClinicalTrials.gov ID
- NCT05546541
- Acronym / sponsor ID
- Nutririsk / Nutririsk
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 88 participants (estimated)
- Lead sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioUniversity, hospital or other
- Study start
- 29 Sep 2021 (actual)
- Primary completion
- 30 Jun 2023 (estimated)
- Study completion
- 30 Jun 2024 (estimated)
- First posted
- 21 Sep 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The general purpose of this study is to evaluate the relation between the nutritional status of patients, the features of the orthobiologics products used for patients' treatment and the clinical outcomes after one-step conservative regenerative treatment for knee osteoarthritis.
Detailed description
The general purpose of this monocentric, observational with additional procedure (extra routine blood sampling, questionnaires and measurement of Nutritional status), prospective and non-controlled study is to evaluate the relation between the nutritional status of patients, the features of the orthobiologics products used for patients' treatment and the clinical outcomes after one-step conservative regenerative treatment (Platelete rich plasma and micro-fragmented adipose tissue injections) for knee osteoarthritis.The primary outcome of the study will be the identification of the proportion of responders and non-responders patients to the orthobiologic treatment (according to OMERACT-OARSI criteria) at 6-month follow-up. Another primary outcome will be the nutritional status identification of the same patients.
For these purposes the responder or non-responder patients will be identified based on the results of the Visual Analogue Scale (VAS) [the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100; a higher score indicates greater pain intensity no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm)], Tegner-Lysholm Activity Scale and Knee Injury (Scores range from 0=worse disability to 100=less disability) and Osteoarthritis Outcome score (KOOS) (the score is a percentage score from 0 to 100, 0 representing extreme problems and 100 representing no problems) according to the parameters established by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) and Osteoarthritis Research Society International (OARSI) [they cannot be represented by a range of values]. The secondary outcomes of the study will be:
- the identification of the proportion of responders and non-responders patients to the orthobiologic treatment (according to OMERACT-OARSI criteria) at 2 and 12-month follow-up and of their related nutritional status;
- the characterization of the orthobiologic products used for the patient's treatment.
After the ethics committee approval, patients meeting the inclusion criteria undergoing conservative knee regenerative medicine treatments with orthobiologics and participating to the observational study "REGAIN" will be enrolled into the study. The PROMs will be completed by patients based on their clinical condition and on the specific treatment they will receive at the REGAIN Center. The aforementioned PROMs include but are not limited to:
- VAS, Tegner-Lysholm Activity Scale, KOOS. Patients will be asked to filled the PROMs at the time of the enrollment (before the treatment) and then at 2, 6 and 12 months after the treatment.
Blood and nutritional information will be collected only the day of the treatment to allow for evaluation of the possible association between patients' characteristics and treatment outcomes. Blood sampling will be performed to carry out the following laboratory analysis, in detail: complete blood count (cell number/dl), blood glucose (mg/dl), hemoglobin A1C (HbA1c) (mmol/mol), creatinine (mg/dl), Glutamic Oxaloacetic Transaminase (GOT) and Glutamic-Pyruvic Transaminase (GPT) (U/L), C reactive protein (mg/dl), triglycerides (mg/dl), total cholesterol(mg/dl), HDL(mg/dl).
In particular, for patients undergoing a Platelet Rich Plasma (PRP) treatment, a blood sample is already routinely harvested and therefore only an extra test tube will be added to test blood glucose (mg/dl), hemoglobin A1C (HbA1c) (mmol/mol), creatinine (mg/dl), GOT and GPT transaminases (U/L), C reactive protein (mg/dl), triglycerides (mg/dl), total cholesterol(mg/dl), HDL(mg/dl). For patients undergoing a treatment with microfragmented adipose tissue, an ad hoc blood collection will be carried out by filling two test tubes.
Nutritional information include anthropometric measurements, diet history and food consumption questionnaire (24h recall, "How much do i really eat?", Italian Mediterranea Index, anamnesi). Anthropometric measurements include weight (kg) and height (m), waist circumference (cm), arm circumference measurements (cm), biceps, triceps, subscapular and suprailiac folds measurement (mm) (plicometry) through the use of the skinfolder. It should be noted that the skinfolder is only one of the tools used to evaluate the patient's nutritional status, without diagnostic purposes and without the will to investigate anything about the device.
Concerning the orthobiologics characterization, PRP and microfragmented adipose tissue will undergo to different evaluations as per the observational study protocol "REGAIN".
In addition, for the purpose of this study, isolation and characterization of extracellular vesicles derived from PRP and micro fragmented adipose tissue will be performed, in order to deepen the orthobiologic characterization. The following techniques will be applied, where appropriate:
- Count and identification of cells from PRP and microfragmented adipose tissue (hemacytometer, nucleocounter, flow cytometry);
- Extracellular vesicle isolation, count and dimensional analysis (ultracentrifuge, Nanosights);
- Extracellular vesicle marker identification (flow cytometry).
These data will be analyzed for their possible association with nutritional status of the patient and clinical outcomes.
Regardless the specific protocol or investigation, the analysis will not include genomic DNA or diagnostic analysis. All samples (blood and tissues) will be analyzed at Istituto Ortopedico Galeazzi and destroyed at the end of the study. Total duration of this study is of 36 months after approval of Ethical Committee.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| subjects normal weight undergo to PRP treatment | – | –subjects with body mass index (BMI) considered normal weight (≥18.5 and ≤25) undergo to Platelet-Rich Plasma (PRP) treatment. |
| subjects overweight undergo to PRP treatment | – | –subjects with BMI values that exceed the normal weight range (BMI>25) undergo to PRP treatment. |
| subjects with normal weight undergo to microfragmented adipose tissue treatment | – | –subjects with BMI within the considered normal weight range (≥18.5 e ≤25) and undergo to microfragmented adipose tissue treatment. |
| subjects overweight undergo to microfragmented adipose tissue treatment | – | –subjects with BMI values that exceed the normal weight range undergo to microfragmented adipose tissue treatment. (BMI>25). |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients affected by knee osteoarthritis undergoing conservative regenerative medicine procedures with autologous material at IRCCS Istituto Ortopedico Galeazzi and participating to the observational study "REGAIN" will be enrolled for this study: 88 patients will be needed: 1. 22 subjects with body mass index (BMI) considered normal weight (≥18.5 and ≤25) undergo to Platelet-Rich Plasma (PRP) treatment; 2. 22 subjects with BMI>25 undergo to PRP treatment; 3. 22 subjects with BMI ≥18.5 and ≤25 undergo to microfragmented adipose tissue treatment; 4. 22 subjects with BMI >25 undergo to microfragmented adipose tissue treatment.
Key inclusion criteria (6 listed)
- males and females ≥18 and ≤ 65 years;
- presence of knee osteoarthritis;
- indication to regenerative medicine treatments PRP or microfragmented adipose treatment;
- participation to the observational study "REGAIN";
- patients with BMI ≥18.5;
Key exclusion criteria (2 listed)
- patients with BMI <18.5;
- patients who are not able to comply with the study schedule.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
6 months follow-up, responders and not responders
Time frame: 6 months after treatment
Identification of the proportion of responders and non-responders patients to the orthobiologic treatment (according to OMERACT-OARSI criteria) at 6-month follow-up.
Identification of the nutritional status of patients: Complete blood count
Time frame: 10 minutes before the treatment
Complete blood count (cell number/dl)
Identification of the nutritional status of patients: Blood glucose
Time frame: 10 minutes before the treatment
Blood glucose (mg/dl) measurement
Identification of the nutritional status of patients: blood Hemoglobin A1C (HbA1c)
Time frame: 10 minutes before the treatment
Hemoglobin A1C (HbA1c) (mmol/mol) measurement
Identification of the nutritional status of patients: blood creatinine
Time frame: 10 minutes before the treatment
Creatinine (mg/dl) measurement
Identification of the nutritional status of patients: blood Glutamic-Oxaloacetic Transaminase GOT (U/L)
Time frame: 10 minutes before the treatment
Glutamic-Oxaloacetic Transaminase GOT (U/L) measurement
Identification of the nutritional status of patients: blood Glutamate Pyruvate Transaminase GPT
Time frame: 10 minutes before the treatment
Glutamate Pyruvate Transaminase GPT (U/L) measurement
Identification of the nutritional status of patients: blood C reactive protein
Time frame: 10 minutes before the treatment
C reactive protein (mg/dl) measurement
Identification of the nutritional status of patients: blood Triglycerides
Time frame: 10 minutes before the treatment
Triglycerides (mg/dl) measurement
Identification of the nutritional status of patients: blood total cholesterol
Time frame: 10 minutes before the treatment
Total cholesterol (mg/dl) measurement
Identification of the nutritional status of patients: blood High Density Lipoprotein HDL
Time frame: 10 minutes before the treatment
High Density Lipoprotein HDL (mg/dl) measurement
Anthropometric measurement: weight
Time frame: 10 minutes before the treatment
weight (kg) measurement
Anthropometric measurement: height
Time frame: 10 minutes before the treatment
height (m) measurement
Anthropometric measurement: waist circumference
Time frame: 10 minutes before the treatment
waist circumference (cm) measurement
Anthropometric measurement: arm circumference measurements
Time frame: 10 minutes before the treatment
arm circumference measurements (cm)
Anthropometric measurement: biceps folds measurement
Time frame: 10 minutes before the treatment
biceps folds measurement (mm)
Anthropometric measurement: triceps folds measurement
Time frame: 10 minutes before the treatment
triceps folds measurement (mm)
Anthropometric measurement: subscapular folds measurement
Time frame: 10 minutes before the treatment
subscapular folds measurement (mm)
Anthropometric measurement: suprailiac folds measurement
Time frame: 10 minutes before the treatment
suprailiac folds measurement (mm)
3 secondary outcomes
2 months follow-up, responders and not responders
Time frame: 2 months after treatment
12 months follow-up, responders and not responders
Time frame: 12 months after treatment
The characterization of the orthobiologic products.
Time frame: 15 minutes after the treatment
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2022.
- Individual participant dataSharing planned: Undecided
Related trials for Musculoskeletal Diseases
Active, not recruitingPhase 3
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Active, not recruitingPhase 1
Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Active, not recruitingPhase 3
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Recruiting
Oral Nutritional Optimization in Total Joint Arthroplasty
Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
IRCCS Galeazzi orthopaedic institute
Milan, Italy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Musculoskeletal Diseases and Osteoarthritis, Knee, run by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
6 months follow-up, responders and not responders (time frame: 6 months after treatment). The study lists 19 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2022.